California Healthcare Institute Board Elects New Member

LA JOLLA, Calif.--(BUSINESS WIRE)-- CHI-California Healthcare Institute announced today the election of Rick Winningham, who serves as CEO of South San Francisco-based Theravance, to serve on the CHI board of directors. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.

“We are pleased to welcome Theravance to our board,” said David L. Gollaher, Ph.D., CHI president and CEO. “Theravance is working to advance important innovations to patients in need. Rick will help inform our approach to the key issues facing our industry today, from FDA regulation to coverage and payment for novel therapeutics.”

Winningham joined Theravance as chief executive officer and member of the board of directors in October 2001, and was appointed chairman of the board in April 2010. Since assuming the role of CEO, Theravance has successfully transitioned from a private research-based small molecule discovery company to a public company with a robust portfolio of product candidates, both in clinical development and on the market. Prior to joining Theravance, Winningham held various management positions with Bristol-Myers Squibb and its predecessor, Bristol-Myers, since 1986. During his tenure with BMS, he was associated with the development and commercialization of several major pharmaceutical products, such as Taxol, Paraplatin, Zerit, Videx, Reyataz, and Abilify. He holds a bachelor’s degree from Southern Illinois University and a master’s of business administration from Texas Christian University. He serves the board of Jazz Pharmaceuticals Inc. and is a member of the external advisory board for the College of Business and Administration and Business Hall of Fame at Southern Illinois University.

About CHI

CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is www.chi.org. Follow us on Twitter @calhealthcare and Facebook.

Editorial note: photo available upon request.



CONTACT:

California Healthcare Institute
Nicole Beckstrand, 858-456-8881
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical  Research  Science  Managed Care

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.